Summary Eukaryotic cell cycle progression is controlled by a host of cyclin/cyclin-dependent kinases (Cdks), that are themselves regulated by multiple factors, including a group of small cyclin-Cdk inhibitor proteins (pl5, p16, p21 and p27). The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the studies of p16. p53 is frequently mutated in thyroid carcinomas and p21/Wafl is a downstream effector of p53. It is conceivable that genetic defects of genes downstream in the p53 pathway could also be oncogenic. We, therefore, examined a series of 57 thyroid tumour specimens (eight follicular adenomas and 49 carcinomas) for deletion and point mutation of the p21/Wafl gene. Three different kinds of deletions ranging from 349 to 450 bp were detected in five papillary carcinoma specimens by reverse transcription-polymerase chain reaction (RT-PCR). All the deletions were involved in the second exon of the p21/Wafl gene. RT-PCR single strand conformational polymorphism (SSCP) analysis of remaining samples failed to reveal any point mutations in the coding region of the gene, except for a polymorphism at codon 31 (Ser to Arg). Genomic Southern blot analysis did not demonstrate any gene deletion or rearrangement in these samples, indicating abnormal RNA splicing may be involved. Analysis of intron-exon boundary and the coding region of the second exon did not reveal any mutation except for a point mutation (C to G) located 16 bp downstream from the splice donor site of the second intron in three out of five samples with p21/Wafl deletions. Whether the mutation plays any role in aberrant RNA splicing remains to be determined. Among the five samples with p21/Wafl gene deletions, none of them simultaneously carried a p53 or retinoblastoma (Rb) gene mutation. No p21/Wajl abnormality was found in the benign adenomas. Thus, 12.5% (5/40) of thyroid papillary carcinoma specimens harboured p21/Wafl gene deletions. Our data suggest that p21/Wafl gene deletion is involved in thyroid carcinogenesis and may play an important role in thyroid cell transformation.
Progression of eukaryotic cells through the cell cycle is regulated by a family of serine/threonine kinases, the cyclindependent kinases (Cdks), whose catalytic activity is modulated by association with different cyclins, which function as regulatory subunits (Norbury and Nurse, 1992; Hunter and Pines, 1994) . Sequential formation, activation and subsequent inactivation of a series of the cyclin-Cdk complexes is believed to be essential for orderly transitions through the cell cycle. A family of small cyclin-Cdk inhibitor proteins (pl5, p16, p21 and p27) have recently been identified, which bind and inactivate different kinds of Cdks, thus participating in the negative regulation of the cell cycle progression. p15 and p16 inhibit only Cdk4 and Cdk6 among the known Cdks, whereas p21, also known as Wafl (El-Deiry et al., 1993) and CIP1 (Harper et al., 1993) and p27 can inhibit multiple Cdks, including Cdk2, Cdk4 and Cdk5 (Xiong et al., 1993; Zhang et al., 1993) .
The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the studies of p16. It has been found that p16 was frequently deleted or mutated in a wide variety of human cancer cell lines, as well as in several specific types of primary tumours (Kamb et al., 1994; Schmidt et al., 1994; Mori et al., 1994; Jen et al., 1994) , indicating that p16 functions as a tumour suppressor. Although p21/Wafl inhibits growth of human tumour cell lines when introduced by transfection (El-Deiry et al., 1993) , there is only limited information that the p21/Wafl gene is mutated or deleted in human tumours (Bhatia et al., 1995) .
The p21/Wafl gene is located at 6p21.2 and encodes a protein of 164 amino acids (El-Deiry et al., 1993) . Its transcription can be activated by the tumour-suppressor p53, thus providing a critical link between the tumour-suppressing activity of p53 and the cell cycle control. We have previously found p53 mutations (Zou et al., 1993a; Farid et al., 1994) in 24% and retinoblastoma (Rb) mutations or deletions in 55% of 49 thyroid carcinoma specimens. The present study was undertaken to find out whether p21/Wajl is involved in thyroid carcinogenesis and the extent to which abnormalities of p21/WaJl correlate with those of p53 and Rb.
Materials and methods
All tumour specimens were obtained at surgery and were immediately frozen in liquid nitrogen and stored at -70°C until processed. The clinical staging of thyroid tumours was based on the TNM classification introduced in 1987 by the International Union Against Cancer (Hermanek and Sobin, 1987) . Fifty-seven thyroid tumours were studied: eight benign adenomas, 40 papillary, four follicular and five anaplastic carcinomas.
Full-length human p21/WaJl cDNA probe was obtained by reverse transcription-polymerase chain reaction (RT-PCR) using two flanking primers (see below). The primers were based on the published p21/ Wafl cDNA sequence . The resulting PCR product was verified by DNA sequencing following subcloning into a TA cloning vector (Invitrogen Co., San Diego, CA, USA).
RT-PCR and SSCP procedure Total RNA was extracted by the guanidinium thiocyanatephenol-chloroform method as described previously (Zou et al., 1993b The remaining samples were analysed by SSCP for the presence of point mutations. Significant electrophoretic mobility shift was detected in six specimens. Sequence analysis revealed a single nucleotide substitution at codon 31 (AGC to AGA), changing Ser to Arg ( Figure 5 ) in all of them. This substitution was reported to be a polymorphism (Chedid et al., 1994; Bhatia et al., 1995) .
In order to find out whether p21/Wa/l deletions were also present in the genomic DNA of those samples, Southern blot analysis was performed. As shown in Figure 4 , no apparent gene deletion, rearrangement or amplification was present, indicating that abnormal RNA splicing may be involved in the deletion of the p21/Wafl gene.
Given that all the deletions are located within the second exon of the p21/Wall gene ( Figure 5 ), we next amplified by PCR the second exon from tumour genomic DNA and examined the intron-exon boundary and the coding region to see if there are any mutations which may lead to aberrant RNA splicing. The PCR products were cloned into a TA vector and a minimum of five clones from each sample were sequenced. As shown in Figure 5 , the entire second exon was skipped in mutant A and partial second exon was spliced out, probably by using potential cryptic splice sites: 5'-CA....AG-3' in mutant B and 5'-AC....TG-3' in mutant C, respectively, although no mutations were found at splice sites surrounding the second exon or within the exon. However, one point mutation (C to G) was found in the second intron 16 bp from 5' splice site. This mutation was present in samples with DNA extraction and Southern blot hybridisation Genomic DNA from tumour samples was extracted as previously described (Sambrook et al., 1989) . Southern blot analysis was performed by digesting 10 ,ug DNA with EcoRI, fractionated on 1% agarose gel and blotted onto a nylon membrane (Hybond-N, Amersham) by capillary transfer. The DNA on the filter was then sequentially hybridised with probes for p21/Wafl and human thyrotropin receptor. Probe labelling and hybridisation were performed as described previously (Zou et al., 1995) .
Results
The coding region of p21/Wajl cDNA was examined for deletion and/or point mutation by RT-PCR and SSCP in 57 thyroid tumour specimens (eight benign adenomas, 49 carcinomas). The RT -PCR products were analysed on 1.8% agarose gel following ethidium bromide staining. Smaller than the expected 561 bp fragments were observed in five papillary carcinoma specimens (Figure 1 ), ranging from 100 to 220 bp. Normal-sized fragments were also present in two of the five samples. Southern blot analysis of the RT-PCR products could, however, detect normalsized fragments as well as the small fragments in all five samples (data not shown). These small fragments could not be amplified from eight benign adenomas or peripheral lymphocytes from ten individuals without known history of thyroid tumours. They were subsequently subcloned and sequenced. As shown in Figures 2 and 3 (Dl, D3 and E) implicated in the control of passage through the restriction point of cell cycle (Xiong et al., 1992; Koff et al., 1992; Dulic et al., 1992; Pagano et al., 1993) . PCNA is the auxilliary protein of DNA polymerase delta (Bravo et al., 1987) and is thought to be involved in DNA replication and repair processes (Prelich et al., 1987; Shiviji et al., 1992) . p21/Waft interacts with and inhibits both Cdk2
and PCNA, thus controlling cell cycle progression and DNA replication (Waga et al., 1994 Given that gene deletion and rearrangement are not found in the tumour genomic DNA, abnormal RNA splicing is probably the cause of p21/Wafl deletion. The entire second exon is skipped in mutant A. The common causes for exon skipping include: (1) mutations in the conserved sequence at the 5' donor site or 3' acceptor site (Green, 1986; Zielenski et al., 1995) . Most reported cases of exon skipping are due to a single base substitution that changes the universal AG dinucleotide at the 3' splice site of the intron (Green, 1986; (2) mutations in the exon (Dietz et al., 1993; Matsuo et al., 1991; Wakamatsu et al., 1992) . The exonic mutations would either activate a cryptic splice site (Matsuo et al., 1991; Wakamatsu et al., 1992) , or interfere with splicing factor binding or RNA secondary structure (Dietz et al., 1993) . Although we could not find any mutations in the conserved splicing sequences surrounding the second exon and within the exon, some uncommon events such as mutations in the second intron or beyond the region we have examined may participate in the exon skipping. The potential cryptic 5' splice site (5'-CA....AG-3') used in mutant B and both splice sites (5'-AG...TG-3') in mutant C do not follow the 5'GT....AG-3' rule. The GT-AG rule describes the splicing junctions of eukaryotic nuclear genes and is highly conserved in most, if not all, mammalian cells (Padgett et al., 1986) . Utilisation of unconserved cryptic splice sites in mutants B and C may suggest that a single or multiple splicing factor defect may be involved in the abnormal splice site selection, and a partial second exon deletion.
In the present study, we were unable to find any samples having both p21/Wafl and p53 or Rb mutations. It is known that radiation induces thyroid tumorigenesis, and recent data have shown that radiation-induced G1 arrest in thyroid cells is selectively mediated by the p53-p21/Wafl pathway (Namba et al., 1995) . p-53induced p21/Wafl participates in the GI/S checkpoint, and inhibits multiple Cdks, including Cdk4, which stimulates cell division by phosphorylation of Rb and release of E2F transcription factor. Loss of p21/Wajl would probably affect both p53 and Rb tumour-suppressor activities. Thus, p21/Wafl mutation alone may be sufficient to induce thyroid malignancy.
